

RESPONSE TO RESTRICTION REQUIREMENT
U.S. Appl. No. 09/856,035

IN THE CLAIMS:

Please enter the following cancellations, amendments and/or additions:

Claims 1-20. (Cancelled)

Claim 21. (New) A method for treatment of a mammal susceptible to a condition associated with a proliferative disease, the method comprising administering to said mammal an effective amount of a pharmaceutical composition comprising at least one Curcuma extract, wherein said pharmaceutical composition is administrated in combination with radiation.

Claim 22. (New) The method according to Claim 21, wherein the radiation has a wavelength of more than 290 nanometers.

Claim 23. (New) The method according to Claim 22, wherein the wavelength is 400-550 nanometers.

Claim 24. (New) The method according to Claim 21, wherein the pharmaceutical composition comprises curcuminoids.

Claim 25. (New) The method according to Claim 21, wherein the pharmaceutical composition is obtainable by extracting Curcuma rhizomes using a solubilizing lipophilic compound.

Claim 26. (New) The method according to Claim 25, wherein said compound is ethanol.

Claim 27. (New) The method according to Claim 25, wherein said pharmaceutical composition further comprises an aqueous extract of Curcuma.

Claim 28. (New) The method according to Claim 21, wherein said Curcuma extract is an extract of Curcuma longa rhizomes.

RESPONSE TO RESTRICTION REQUIREMENT
U.S. Appln. No. 09/856,035

Claim 29. (New) The method according to Claim 21, wherein said proliferative disease is characterized by an increase in cytokine production.

Claim 30. (New) The method according to Claim 29, wherein said cytokine production is IL-8 production or IL-6 production.

Claim 31. (New) The method according to Claim 21, wherein said proliferative disease is psoriasis.

Claim 32. (New) A method for treatment of a mammal (susceptible to a condition) associated with a fibrinogen disease, the method comprising administering to said mammal an effective amount of a pharmaceutical composition comprising at least one compound present in *Curcuma* rhizomes.

Claim 33. (New) The method according to Claim 32, wherein the pharmaceutical composition comprises a *Curcuma* extract.

Claim 34. (New) The method according to Claim 32, wherein the pharmaceutical composition comprises *curcuminoids*.

Claim 35. (New) The method according to Claim 32, wherein the pharmaceutical composition is obtainable by extracting *Curcuma* rhizomes using a solubilizing lipophilic compound.

Claim 36. (New) The method according to Claim 35, wherein said compound is ethanol.

Claim 37. (New) The method according to Claim 35, wherein said pharmaceutical composition further comprises an aqueous extract of *Curcuma*.

Claim 38. (New) The method according to Claim 32, wherein said method results in a reduction of Apolipoprotein B/Apolipoprotein A-1 quotient in said mammal.

RESPONSE TO RESTRICTION REQUIREMENT
U.S. Appln. No. 09/856,035

Claim 39. (New) The method according to Claim 32,
wherein said *Curcuma* rhizomes are *Curcuma longa* rhizomes.

Claim 40. (New) The method according to Claim 32,
wherein said fibrinogen disease is a cardiovascular disease.
